The role of podoplanin in tumor progression and metastasis

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2997-3006

  Raica, Marius ^a   Cimpean, Anca Maria ^a   Ribatti, Domenico ^b,c  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Lymphatic vessels; Metastasis; Podoplanin; Review; Tumor growth

Indexed keywords

CELL SURFACE PROTEIN; HOMEODOMAIN PROTEIN; PODOPLANIN; PROTEIN LYVE 1; PROTEIN PROX 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3;

CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; GENE CONTROL; GENE SYNTHESIS; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MASTOCYTOMA; MESOTHELIOMA; METASTASIS; NONHUMAN; OVARY TUMOR; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SQUAMOUS CELL CARCINOMA; TESTIS TUMOR; THROMBOCYTE AGGREGATION; TUMOR GROWTH; VASCULAR TUMOR;

DISEASE PROGRESSION; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 55749085491     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Reis-Filho JS and Schraitt FC: Lymphangiogenesis: what do we know? Microsc Res Tech 60: 171-180, 2003.
2. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M and Jackson DG: LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144: 789-801, 1999.
3. Wigle JT and Oliver G: Prox 1 function is required for the development of the murine lymphatic system. Cell 98: 769-778, 1999.
4. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K and Kerjanschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Am J Pathol 154: 385-394, 1999.
5. Straume O, Jackson DG and Akslen LA: Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 9: 250-256, 2003.
6. Beasley NJ, Prevo R, Banerji S, Leek DR, Moore J, van Trappen Ph, Cox G, Harris AL and Jackson DG: Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62: 1315-1320, 2002.
7. Schoppmann SF, Birner P, Studer P and Breiteneder-Geleff S: Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 21: 2351-2355, 2001.
8. Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, Sugiyama K, Partanen T, Yamamoto H and Sasaki T: Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 37: 918-923, 2001.
9. Shayan R, Achen MG and Stacker SA: Lymphatic vessels in cancer metastasis: bridging the gap. Carcinogenesis 27: 1729-1738, 2006.
10. He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P and Alitalo K: Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64: 3737-3740, 2004.
11. Wilting J, Tomarev SI, Christ B and Schweigerer L: Lymphangioblasts in embryonic lymphangiogenesis. Lymphat Res Biol 1: 33-40, 2003.
12. Jeltsch M, Tammela T, Alitalo K and Wilting J: Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res 314: 69-84, 2003.
13. Saintigny P, Morere JF, Breau JL, Bernaudin JF and Kraemer M: Lymph node metastasis as a new target for cancer treatment. Targ Oncol 2: 49-57, 2007.
14. Cao Y: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 5: 735-743, 2005.
15. Ji RC: Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: new insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25: 677-694, 2006.
16. Sinzelle E, Van Huyen JP, Breiteneder Geleff S, Braunberger E, Deloche A, Kerjanschki D and Bruneval P: Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology 37: 93-94, 2000.
17. Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G and Oberhuber G: Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 7: 93-97, 2001.
18. Cunnick GH, Jiang WG, Gomez KF and Mansel RE: Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 17: 863-870, 2002.
19. Sedivy R, Beck-Mannagetta J, Haverkampf C, Battistutti W and Honigschnable S: Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J Oral Pathol Med 32: 455-460, 2003.
20. Nose K, Saito H and Kuroki T: Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ 1: 511-518, 1990.
21. Wetterwald A, Hofstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H and Atkinson M: Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18: 125-132, 1996.
22. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G and Kerjanschki D: Podoplanin, novel 43 kDa membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151: 1141-1152, 1997.
23. Matsui K, Breiteneder Geleff S and Kerjaschki D: Epitope specific antibodies to the 43 kDa glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol 9: 2013-1026, 1998.
24. Kriehuber E, Breitender-Gelleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D and Maurer D: Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 194: 797-808, 2001.
25. Boucherot A, Schreiber R, Pavenstadt H and Kunzelmann K: Cloning and expression of the mouse glomerular podoplanin homologue gp38P. Nephrol Dial Transplant 17: 978-984, 2002.
26. Hantusch B, Kalt R, Krieger S, Puri C and Kerjanschki D: Spl/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol 8: 20, 2007.
27. Kaneko MK, Kato Y, Kitano T and Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 378: 52-57, 2006.
28. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M and Tsuruo T: Molecular identification of Aggrus/T1α as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278: 51599-51605, 2003.
29. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Inoue K, Inoue O, Ozaki Y and Narimatsu H: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 3: 1-8, 2007.
30. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Narimatsu H and Ozaki Y: Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation by cancer cells. J Biol Chem 282: 25993-26001, 2007.
31. Schmid H, Henger A, Cohen CD, Frach K, Gröne HJ, Schlöndorff D and Kretzler M: Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc Nephrol 14: 2958-2966, 2003.
32. Levidiotis V and Power DA: New insights into the molecular biology of the glomerular filtration barrier and associated disease. Nephrology 10: 157-166, 2005.
33. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Oliver G and Detmar M: T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556, 2003.
34. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D and Baumal R: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 80: 569-578, 2000.
35. Xuan M, Fang YR, Wato M, Hata S and Tanaka A: Immunohistochemical co-localization of lymphatics and blood vessels in oral squamous cell carcinomas. J Oral Pathol Med 34: 334-339, 2005.
36. Fiedler U, Christian S, Koidl S, Kerjanschki D, Emmett MS, Bates DO, Christofori G and Augustin HG: The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol 168: 1045-1053, 2006.
37. Kreuger J, Nilsson I, Kerjaschki D, Petrova T, Alitalo K and Claesson-Welsh L: Early lymph vessel development from embryonic stem cells. Arterioscler Thromb Vasc Biol 26: 1073-1078, 2006.
38. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi M, Narimatsu H, Mishima K and Osawa ML: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 349: 1301-1307, 2006.
39. Petrova TV, Makinen T, Makela TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Yla-Herttuala S and Alitalo K: Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 21: 4593-4599, 2002.
40. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166: 913-921, 2005.
41. Scholl FG, Gamallo C, Vilar S and Quintanilla M: Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J Cell Sci 112: 4601-4613, 1999.
42. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D and Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272, 2006.
43. Gröger M, Loewe R, Holnthoner W, Embacher R, Pillinger M, Herron SG, Wolff K and Petzelbauer P: II-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol 173: 7161-7169, 2004.
44. Suzuki H, Kato Y, Kaneko MK, Okita Y, Narimatsu H and Kato M: Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma. FEBS Lett 582: 341-345, 2008.
45. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Yla-Herttuala S and Alitalo K: Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7: 199-205, 2001.
46. Ji RC, Eshita Y and Kato S: Investigation of intratumoural and peritumoral lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours. Int J Exp Path 88: 257-270, 2007.
47. Vanderbilt JN and Dobbs LG: Characterization of the gene and promoter for RTI40, a differentiation marker of type I alveolar cells. Am J Respir Cell Mol Biol 19: 662-671, 1998.
48. Alitalo K, Tammela T and Petrova TV: Lymphangiogenesis in development and human disease. Nature Insight 438: 946-953, 2005.
49. Schoppmann SF, Fenzl A and Laengle F: Surgical oncology: impact of lymphangiogenesis for metastasis formation. Eur Surg 37: 153-158, 2005.
50. Gombos Z, Xu X, Chu CS, Zhang PJ and Acs G: Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 11: 8367-8371, 2005.
51. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I and Dome B: Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11: 7344-7353, 2005.
52. Adachi Y, Nakamura H, Kitamura Y, Taniguchi Y, Araki K, Shomori K, Horie Y, Kurozawa Y, Ito H and Hayashi K: Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases. Pathol Intern 57: 171-177, 2007.
53. Fenzl A, Schopmann SF, Geleff S, Birner P, Wrba F, Herberger B, Teleky B, Herbst F, Kührer I, Jakesz R and Längle F: Vascular endothelial growth factor-C expression and lymphangiogenesis in colorectal cancer. Eur Surg 38: 149-154, 2006.
54. Ohno F, Nakanishi H, Abe A, Seki Y, Kinoshita A, Hasegawa Y, Masae T and Kurita K: Regional differences in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: an analysis in comparison with angiogenesis. J Oral Pathol 36: 281-289, 2007.
55. Nakamura Y, Yasouka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K: Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 91: 125-132, 2005.
56. Choi WWL, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C and Young AN: Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18: 143-152, 2005.
57. Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hoffman T, Nagy K, Gnant M, Horvat R, Jakesz R and Birner P: Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 99: 135-141, 2006.
58. Wobster M, Siedel C, Schrama D, Bröcker EB, Becker JC and Vetter-Kauczok CS: Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Arch Dermatol Res 297: 352-357, 2006.
59. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Kowalski H and Oberhuber G: Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res 20: 2981-2985, 2000.
60. Sipos B, Klapper W, Kruse ML, Kalthoff H, Kerjanschki D and Klöppel G: Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol 165: 1187-1197, 2004.
61. Rubbia-Brandt L, Terris B, Giostra E, Dousset B, Morel Ph and Pepper MS: Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res 10: 6919-6928, 2004.
62. Van der Auwera I, Cao Y, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY and Vermeulen PB: First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 95: 1611-1625, 2006.
63. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S and Ristamaki R: Intratumoral lymphatics are essential for the metastatic spread and progression in squamous cell carcinomas of the head and neck region. Cancer Res 63: 1920-1926, 2003.
64. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC and Detmar M: Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162: 1951-1960, 2003.
65. Omachi T, Kawai Y, Mizuno R, Nomiyama T, Miyagawa S, Ohhashi T and Nakayama J: Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance. Cancer Lett 246: 167-172, 2007.
66. Van der Auwera I, van der Eynden GG, Colpaert CG, van Laere SJ, van Dam P, Van Marck EA, Dirix LY and Vermeiden PB: Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 11: 7637-7642, 2005.
67. Jain RK and Fenton BT: Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst 94: 417-421, 2002.
68. Marinho VFZ, Metze K, Sanches FSF, Rocha GFS and Gobbi H: Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer 8: 64, 2008.
69. Braun M, Flucke U, Debald M, Walgenbach-Bruenagel G, Walgenbach KJ, Höller T, Pölcher M, Wolfgarten M, Sauerwald A, Keyver-Paik M, Kühr M, Büttner R and Kuhn W: Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res Treat, 2007.
70. Yamada Y, Matsumoto T, Arakawa A, Fkeda S, Fujime M, Komuro Y and Takeda S: Evaluation using a combination of lymphatic invasion on D2-40 immunostain and depth of dermal invasion is a strong predictor for nodal metastasis in extramammary Paget's disease. Pathol Intern 58: 114-117, 2008.
71. Weninger W, Partanen T, Breitender-Gelleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Stürzl M, Kerjanschki D, Alitalo K and Tschachler E: Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 78: 243-251, 1999.
72. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T and Osawa M: Enhanced expression of Aggrus (T1α/podoplanin), a platelet aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 26: 195-200, 2005.
73. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J and Quintanilla M: Characterization of human PA2.26 antigen (T1α-2, podoplanin) a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113: 899-910, 2005.
74. Kimura N and Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int 55: 83-86, 2005.
75. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N and Tsuruo T: Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 23: 8552-8556, 2004.
76. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T and Matsutani M: Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol 111: 563-568, 2006.
77. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T and Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 111: 483-488, 2006.
78. Suurmeijer AJH and Fletcher CDM: Papillary haemangioma. A distinctive cutaneous haemangioma of the head and neck area containing eosinophilic hyaline globules. Histopathol 51: 638-648, 2007.
79. Naqvi J, Ordonez NG, Luna MA, Williams MD, Weber RS and El-Naggar AK: Epitheloid hemangioendothelioma of the head and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol 2: 25-30, 2007.
80. Hansen T, Katenkamp K, Bittinger F, Kirkpatrick CJ and Katenkamp D: D2-40 labeling in lymphangiomyoma/ lymphangiomyomatosis of the soft tissue: further evidence of lymphangiogenic tumor histogenesis. Virchows Arch 450: 449-453, 2007.
81. Fukunaga M: Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathol 46: 396-402, 2005.
82. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K and Boshoff C: Kaposi sarcoma herpes virus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36: 687-693, 2004.
83. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, Libermann T, Dezube BJ, Fingeroth JD and Detmar M: Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpes virus. Nat Genet 36: 683-685, 2004.
84. Chu AY, Litzky LA, Pasha TL, Acs G and Zhang PJ: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 18: 105-110, 2005.
85. Ordonez NG: The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 19: 34-48, 2006.
86. Ordonez NG: What are the current best immunohistochemical markers for the diagnosis of epitheloid mesothelioma? A review and update. Human Pathol 38: 1-16, 2007.
87. Padgett DM, Cathro HP, Wick MR and Mills SE: Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol 32: 123-127, 2008.
88. Sonne SB, Herlihy AS, Hoei-Hansen CE, Nielsen JE, Almstrup K, Skakkebaek NE, Marks A, Leffers H and Rajpert-De Meyts E: Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch 449: 200-206, 2006.
89. Zayed AE, Abd-Elnaeim MM, Abd-Elghaffar SKh, Hild A, Brehm R and Steger K: Prenatal development of murine gonads with special reference to germ cell differentiation: a morphological and immunohistochemical study. Andrologia 39: 93-100, 2007.
90. Biermann K, Klingmuller D, Koch A, Pietsch T, Schorle H, Büttner R and Zhou H: Diagnostic value of markers M2A, OCT3/4, AP-2γ, PLAP and c-KIT in the detection of extragonadal seminomas. Histopathol 49: 290-297, 2006.
91. Shibahara J, Kashima T, Kikuchi Y, Kunita A and Fukayama M: Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448: 493-499, 2006.
92. Huse JT, Pasha TL and Zhang PJ: D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma. Acta neuropathol 113: 87-94, 2007.
93. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A and Inai K: Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Intern 57: 190-199, 2007.
94. Maeda M and Hino O: Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Intern 56: 649-654, 2006.
95. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T and Fujita N: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170: 1337-1347, 2007.
96. Moustakas A and Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520, 2007.
97. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S and Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119: 4541-4553, 2006.
98. Wicki A and Christofori G: The potential role of podoplanin in tumour invasion. Br J Cancer 96: 1-5, 2007.
99. He Y, Kokaki K, Karpanen T, Koshikawa K, Ila-Herttuala S, Takahashi T and Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. JNCI94: 819-825, 2002.
100. Pepper MS, Tille JC, Nisato R and Skobe M: Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314: 167-177, 2003.
101. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H and Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191, 2001.
102. Jain RK and Padera TP: Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy. J Natl Cancer Inst 94: 785-787, 2002.
103. Fukumoto S, Morifuji M, Katakura Y, Ohishi M and Nakamura S: Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 22: 31-38, 2005.
104. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M and Ishikura H: Rapamycin, a specific inhibitor of the mammalian target rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98: 726-733, 2007.
105. Wong SY, Haack H, Crowley D, Barry M, Bronson RT and Hynes RO: Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 65: 9789-9798, 2005.